SG293 / Sana Biotech - LARVOL DELTA

Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293 (ASGCT 2026) - "SG293 represents a differentiated approach for enabling potent and precise in vivo CAR-T therapy for both oncology and autoimmune indications, potentially avoiding key off-target concerns. Beyond SG293, the fusogen, transgene, and other components of our VLP platform are readily modular for targeting different cells and delivering diverse therapeutic payloads."

CAR T-Cell Therapy • IO biomarker • Preclinical • Immunology • CD20 • CD8

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs (GlobeNewswire) - "The data were reported in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting....'Data presented at ASGCT highlight the fusogen platform’s potential to enable development of therapies that offer off-the-shelf treatment options for patients with blood cancers, B cell-mediated autoimmune disorders, and multiple myeloma. The data support our strategy of advancing SG293 into the clinic for the treatment of non-Hodgkin lymphoma (NHL) later this year and SG227, a BCMA-targeted in vivo CAR T cell therapy, into the clinic for the treatment of multiple myeloma as early as mid-2027'."

New trial • Preclinical • Immunology • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting (GlobeNewswire)

Preclinical • Immunology • Oncology

Sana intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases. The company expects to file an IND for SG293 as early as 2027. (GlobeNewswire)

IND • Immunology • Oncology